Alps Advisors Inc Pro Qr Therapeutics N.V. Transaction History

Alps Advisors Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 11, 2022	SELL	$0.56 - $1.0 $41,322 - $73,790	-73,790 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$0.9 - $8.39 $7,693 - $71,717	-8,548 Reduced 10.38%	73,790 $67,000
Q4 2021 Feb 09, 2022	BUY	$6.58 - $8.44 $541,784 - $694,932	82,338 New	82,338 $660,000
Q2 2021 Aug 11, 2021	SELL	$5.75 - $7.59 $521,605 - $688,519	-90,714 Closed	0 $0
Q1 2021 May 07, 2021	BUY	$4.14 - $9.22 $4,769 - $10,621	1,152 Added 1.29%	90,714 $600,000
Q4 2020 Feb 03, 2021	BUY	$3.58 - $4.85 $91,701 - $124,232	25,615 Added 40.06%	89,562 $376,000
Q3 2020 Nov 04, 2020	SELL	$4.79 - $6.3 $20,209 - $26,579	-4,219 Reduced 6.19%	63,947 $306,000
Q2 2020 Aug 05, 2020	BUY	$4.5 - $6.53 $306,747 - $445,123	68,166 New	68,166 $414,000
Q4 2019 Feb 07, 2020	SELL	$5.84 - $10.51 $452,477 - $814,304	-77,479 Closed	0 $0
Q3 2019 Nov 04, 2019	SELL	$5.76 - $9.44 $22,296 - $36,542	-3,871 Reduced 4.76%	77,479 $446,000
Q2 2019 Aug 07, 2019	BUY	$9.1 - $15.55 $740,285 - $1.26 Million	81,350 New	81,350 $740,000

17.6M

37.7K

21.3K

Ticker PRQR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,362,096
Market Cap $161M
Description
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clin...

Get notified when there are updates to the investment portfolio of Alps Advisors Inc, based on Form 13F filings with the SEC.

Stay updated on Alps Advisors Inc with notifications on news.